CDEK
← All drugs Report issue

bevacizumab

Trade name: avastin

mAbapprovedCOVID-19Orphan Drug FDA

Approved

Feb 26, 2004

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal). — Wikipedia

Clinical trial activity

2,466 trials · 1,014 clinical orgs · 6 marketing orgs

Phase 1
527
Phase 2
1880
Phase 3
425
Phase 4
77

Earliest trial started Feb 1, 1998 (NCT00109057)

Timeline

1990s

  1. Jan 1, 1998

    Genentech — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Genentech — Earliest Phase 3 Sponsor(trial)

  2. Nov 6, 2003

    Orphan Drug Designation

  3. Feb 26, 2004

    Genentech — Earliest FDA Approval

  4. Feb 26, 2004

    Genentech — Marketing Organization

  5. Feb 26, 2004

    Genentech — NDA Organization

2010s

  1. Sep 14, 2017

    Amgen — Marketing Organization

  2. Sep 14, 2017

    Amgen — NDA Secondary Org

  3. Jun 27, 2019

    Pfizer — Marketing Organization

  4. Jun 27, 2019

    Pfizer — NDA Secondary Org

2020s

  1. Apr 13, 2022

    Amneal Pharmaceuticals — Marketing Organization

  2. Apr 13, 2022

    Amneal Pharmaceuticals — NDA Secondary Org

  3. Sep 27, 2022

    Celltrion — Marketing Organization

  4. Sep 27, 2022

    Celltrion — NDA Secondary Org

  5. Apr 9, 2025

    Biocon Limited — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedFeb 26, 2004

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 12-igg1
  • abp 215
  • antivegf
  • avastin
  • avastin
  • avastin
  • avastin
  • avastin
  • bevacituzumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab
  • bevacizumab-awwb
  • bevacizumab-awwb
  • mil60
  • r-435
  • rg-435
  • rhumab-
  • rhumab-vegf
  • ro1507
  • vegf
  • vegf
  • vegf
  • vegf-a

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07288034Phase 2Sep 21, 2026City of Hope National Medical Center, National Cancer Institute (NCI)
NCT07271355Phase 3Jul 1, 2026City of Hope National Medical Center, National Cancer Institute (NCI)
NCT07221357Phase 2/Phase 3 (Phase 3)Mar 4, 2026Biontech, Bristol-Myers Squibb
NCT07284849Phase 3Feb 16, 2026Incyte
NCT07291076Phase 1/Phase 2 (Phase 2)Feb 9, 2026Biontech, Bristol-Myers Squibb
NCT07297212Phase 2Jan 31, 2026Biontech, Bristol-Myers Squibb
NCT07059494Phase 4Jan 31, 2026Genentech, Icahn School of Medicine at Mount Sinai
NCT07225270Phase 3Jan 15, 2026Genmab
NCT07274787N/AJan 1, 2026NaviFUS Corporation, University of Cincinnati
NCT07311577Phase 2Jan 1, 2026Jiangsu Cancer Institute & Hospital
NCT07281664N/AJan 1, 2026Sun Yat-Sen University
NCT07276100Phase 2Jan 1, 2026University of Bologna
NCT06971744Phase 2Jan 1, 2026Medical University of South Carolina
NCT07150403Phase 2Dec 31, 2025Federation Francophone de Cancerologie Digestive
NCT06999980Phase 2Dec 31, 2025Bristol-Myers Squibb, Melanoma Institute Australia
NCT07229846Phase 2Dec 31, 2025Harbin Medical University
NCT07239596Phase 1/Phase 2 (Phase 2)Dec 31, 2025Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07244926Phase 2Dec 31, 2025Tianjin Medical University
NCT07286695Phase 2Dec 31, 2025Chinese Academy of Medical Sciences
NCT07298772Phase 1/Phase 2 (Phase 2)Dec 31, 2025Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Showing 20 of 2,466 trials
Page 1 / 124

Organizations

Research & Development (1,014)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GenentechFor profit3355451998
National Cancer Institute (NCI)Government31018141998
RocheFor profit23913142003
University of Texas at HoustonAcademic/Hospital877532001
Harvard UniversityAcademic/Hospital746342001
Sun Yat-Sen UniversityAcademic/Hospital706332011
Fudan UniversityAcademic/Hospital594752011
Duke UniversityAcademic/Hospital493642002
Cornell UniversityAcademic/Hospital423142002
NovartisFor profit39642004
Eli LillyFor profit381332003
Chinese Academy of Medical SciencesAcademic/Hospital372742012
SanofiFor profit36942002
SCRI Development InnovationsFor profit363322003
PfizerFor profit332232003
MerckFor profit301332008
Zhejiang UniversityAcademic/Hospital282252013
Huazhong University of Science and TechnologyAcademic/Hospital272252016
Shahid Beheshti University of Medical SciencesAcademic/Hospital272742005
Bristol-Myers SquibbFor profit261232005
1,014 organizations
Page 1 / 51

Marketing (11)

OrganizationOrg typeRelationshipDate
AmgenFor profitMKTGSep 14, 2017
AmgenFor profitNDA2Sep 14, 2017
Amneal PharmaceuticalsFor profitMKTGApr 13, 2022
Amneal PharmaceuticalsFor profitNDA2Apr 13, 2022
Biocon LimitedFor profitMKTGApr 9, 2025
CelltrionFor profitMKTGSep 27, 2022
CelltrionFor profitNDA2Sep 27, 2022
GenentechFor profitMKTGFeb 26, 2004
GenentechFor profitNDAFeb 26, 2004
PfizerFor profitMKTGJun 27, 2019
PfizerFor profitNDA2Jun 27, 2019